Data Sheet (Cat.No.T15198)

TargetMol
A DRUG SCREENING EXPERT

Edasalonexent

Chemical Properties



CAS No.:	1204317-86-1
Formula:	C31H42N2O3
Molecular Weight:	490.68
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Edasalonexent is an orally bioavailable inhibitor of NF-κB.
Targets(IC_{50})	NF-κB: None
In vitro	Edasalonexent obviously inhibits NF-κB p65-dependent inflammatory responses and downstream proinflammatory genes modulated by p65 in the golden retriever Duchenne muscular dystrophy (DMD) model [2].
In vivo	It causes reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury, after treatment of mdx mice with Edasalonexent for 20 weeks [1].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.038 mL	10.19 mL	20.38 mL
5 mM	0.408 mL	2.038 mL	4.076 mL
10 mM	0.204 mL	1.019 mL	2.038 mL
50 mM	0.041 mL	0.204 mL	0.408 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341.

2. Donovan JM, et al. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639.

Inhibitors · Natural Compounds · Compound Libraries

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481